NextCure announced the availability of a replay for its virtual key opinion leader event discussing positive Phase 1 dose escalation data for SIM0505, an investigational antibody drug conjugate targeting gynecologic cancers such as ovarian and uterine serous carcinoma. The data, presented at ASCO 2026, showed encouraging clinical efficacy and safety, highlighting SIM0505's potential as a new treatment option where current therapies are limited. The company holds exclusive global rights to SIM0505 outside China and continues its development with FDA Fast Track designation for ovarian cancer treatment. Investors and interested parties can access the event replay and related ASCO materials on NextCure's website.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
